Sangamo Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $49,412 | $356 | $481 | $2,041 |
Gross Profit | 49,412 | -2,217 | -2,045 | -940 |
EBITDA | 10,631 | -33,481 | -44,871 | -57,586 |
EBIT | -36,054 | -47,397 | -60,568 | |
Net Income | 10,672 | -36,128 | -49,089 | -60,296 |
Net Change In Cash | 49,412 | 356 | 481 | 2,041 |
Free Cash Flow | 11,644 | -26,884 | -48,663 | -53,209 |
Cash | 39,201 | 27,786 | 55,333 | 45,204 |
Basic Shares | 214,325 | 203,946 | 180,342 | 177,619 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $176,232 | $111,299 | $110,701 | $118,192 |
Gross Profit | -45,325 | 111,299 | 110,701 | 118,192 |
EBITDA | -87,427 | -180,719 | -165,699 | -116,183 |
EBIT | -109,619 | -201,281 | -183,337 | -129,552 |
Net Income | -257,831 | -192,278 | -178,297 | -121,122 |
Net Change In Cash | 176,232 | 111,299 | 110,701 | 118,192 |
Cost of Revenue | -79,682 | 47,806 | 51,348 | |
Free Cash Flow | -245,997 | -243,798 | -256,529 | 155,161 |
Cash | 45,204 | 100,444 | 178,872 | 131,329 |
Basic Shares | 174,444 | 154,345 | 144,568 | 134,449 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.04 |
2024-06-30 | -$0.18 |
2024-03-31 | -$0.27 |
2023-12-31 | -$0.34 |
